Rappaport, Amy R.
Kyi, Chrisann
Lane, Monica
Hart, Meghan G.
Johnson, Melissa L. http://orcid.org/0000-0001-9874-1314
Henick, Brian S. http://orcid.org/0000-0003-2681-0805
Liao, Chih-Yi
Mahipal, Amit
Shergill, Ardaman
Spira, Alexander I.
Goldman, Jonathan W. http://orcid.org/0000-0002-4925-8243
Scallan, Ciaran D.
Schenk, Desiree
Palmer, Christine D. http://orcid.org/0000-0003-3213-0398
Davis, Matthew J.
Kounlavouth, Sonia
Kemp, Lindsey
Yang, Aaron
Li, Yaojun John
Likes, Molly
Shen, Annie
Boucher, Gregory R.
Egorova, Milana http://orcid.org/0000-0002-9917-091X
Veres, Robert L.
Espinosa, J. Aaron
Jaroslavsky, Jason R.
Kraemer Tardif, Lauren D.
Acrebuche, Lindsey
Puccia, Christopher
Sousa, Leiliane
Zhou, Rita
Bae, Kyounghwa
Hecht, J. Randolph
Carbone, David P. http://orcid.org/0000-0003-3002-1921
Johnson, Benny
Allen, Andrew
Ferguson, Andrew R.
Jooss, Karin http://orcid.org/0000-0001-7670-4993
Article History
Received: 11 October 2023
Accepted: 29 January 2024
First Online: 27 March 2024
Competing interests
: A.R.R., M.L., M.G.H., C.D.S., D.S., C.D.P., M.J.D., S.K., L.K., A.Y., Y.J.L., M.L., A. Shen, G.R.B., M.E., R.L.V., J.A.E., J.R.J., L.D.K.T., L.A., C.P., L.S., R.Z., K.B., A.A., A.R.F. and K.J. are stockholders and either current or previous employees at Gritstone bio, Inc. and may be listed as co-inventors on various pending patent applications related to the vaccine platform presented in this study. C.K. received honoraria from OncLive, Total Health, consults/has consulted for Scenic Immunology BV and has received research funding from Bristol Myers Squibb, Merus, Gritstone bio and Acrivon. C.-Y.L. consults/has consulted for AstraZeneca, Genentech, Histosonics, Incyte, Ipsen, QED, Transthera and Boston Scientific and is a speaker for AstraZeneca and Incyte. A.I.S. has a leadership role at NEXT Oncology Virginia; is a stockholder of Eli Lilly; has received honoraria from CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol Myers Squibb and Bayer; has consultant or advisory roles at Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone bio, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Mersana, Daiichi Sankyo/AstraZeneca, Regeneron, Lilly, Black Diamond Therapeutics, Sanofi, Array BioPharma, AstraZeneca/MedImmune, Bristol Myers Squibb and Blueprint Medicines; has received research funding from LAM Therapeutics, Regeneron, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Incyte, Abbvie, Ignyta, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol Myers Squibb, Loxo, Arch Therapeutics, Gristone bio, Plexxikon, Amgen, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, Rubius, Mersana, Blueprint Medicines, Alkermes, Revolution Medicines, Medikine, Synthekine, Black Diamond Therapeutics, BluPrint Oncology, Nalo Therapeutics, Scorpion Therapeutics and ArriVent Biopharma. M.L.J.: financial interests, personal, advisory board: Astellas, Otsuka; financial interests, institutional, research grant: AbbVie, Acerta, Amgen, Apexigen, Arcus, Array, AstraZeneca, Atreca, Beigene, Birdie, Boehringer Ingelheim, Checkpoint Therapeutics, Guardant Health, Genocea, Hengrui, Immunocore, Incyte, Janseen, Jounce, Gritstone bio, Lycera, Merck, Mirati, Oncomed, Regeneron, Ribon, Sanofi, Shattuck Labs, Stem CentRx, Syndax, Takeda, Tarveda, TCR2 Therapeutics, University of Michigan and WindMIL. B.J.: financial interests, personal, advisory board: Gritstone bio, Inc., Incyte, Taiho Oncology; financial interests, personal, research grant: BMS, Syntrix. A.M.: financial interests, personal, advisory board: Taiho, Incyte. J.R.H.: financial interests, personal, advisory board: Ipsen, Merck and Acrotech Biopharma; financial interests, institutional, research grant: ARMO Biosciences, Halozyme, Amgen, Merck, AbbVie, Advaxis, Astellas, Forty Seven, Immunomedics, Lilly, Gritstone bio, GSK and Arcus. The other authors declare no competing interests.